PAVmed (PAVM)
(Real Time Quote from BATS)
$0.46 USD
0.00 (-0.91%)
Updated Aug 7, 2025 01:54 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
PAVM 0.46 0.00(-0.91%)
Will PAVM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PAVM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PAVM
PAVmed (PAVM) Upgraded to Buy: Here's What You Should Know
Lucid Inks New Partnership With VITALExam: Stock to Gain?
PAVM: What are Zacks experts saying now?
Zacks Private Portfolio Services
NeuroPace, Inc. (NPCE) Reports Q3 Loss, Tops Revenue Estimates
Mesa Labs (MLAB) Lags Q2 Earnings and Revenue Estimates
Other News for PAVM
PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025 | PAVM Stock News
PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule | ...
PAVmed gets 180-day extension to regain Nasdaq listing compliance
Lucid says meeting scheduled to determine Medicare coverage for cancer test
PAVmed Inc. Completes First in Human Trial of PortIO Intraosseous Infusion System